| |
RA |
AS |
HC |
Pvalue * |
Pvalue # |
| N |
59 |
61 |
60 |
|
|
| Age (years), mean ± SEM |
58 ± 1.6 |
43.6 ± 1.8 |
46.6 ± 1.8 |
< 0.0001 |
RA vs HC: < 0.0001 |
| Gender (M/F), no. |
12/47 |
46/15 |
13/47 |
**< 0.0001 |
AS vs HC: **< 0.0001 |
| Disease duration (years), mean ± SEM |
10.2 ± 1.1 |
11.7 ± 1.2 |
NA |
NS*** |
|
| Extra articular disease, no. (%) |
| Nodules |
5 (8.4) |
0 |
NA |
|
|
| Uveitis |
0 |
12 (19.6) |
NA |
|
|
| Sicca syndrome |
5 (8.4) |
0 |
NA |
|
|
| Crohn |
0 |
4 (6.5) |
NA |
|
|
| Psoriasis |
0 |
8 (13.1) |
NA |
|
|
| Rheumatoid Factors (%) |
76.3 |
NA |
NA |
|
|
| Anti-CPP antibodies (%) |
76.3 |
NA |
NA |
|
|
| HLA- B27 (%) |
NA |
85.3 |
NA |
|
|
| DAS28, mean ± SEM |
3.9 ± 0.2 |
NA |
NA |
|
|
| HAQ, mean ± SEM |
1.14 ± 0.1 |
NA |
NA |
|
|
| BASDAI, mean ± SEM |
NA |
5.2 ± 0.3 |
NA |
|
|
| BASFI, mean ± SEM |
NA |
4.2 ± 0.3 |
NA |
|
|
| ASDAS, mean ± SEM |
NA |
3.2 ± 0.1 |
NA |
|
|
| Treatments |
| MTX, no. (%) |
33 (55.9) |
|
NA |
|
|
| LFM, no. (%) |
10 (16.9) |
|
NA |
|
|
| Other (SLZ, HCQ), no. (%) |
12 (20.3) |
4 (6.5) |
NA |
|
|
| AINS, no. (%) |
|
44 (72.1) |
NA |
|
|
| CTC, no. (dosage, m ean ± SEM) |
33 (5.9 ± 2.8 mg) |
5 (8.4 ± 2.3 mg) |
NA |
|
|
| ESR (mm/h), mean ± SEM |
26.6 ± 3.3 |
21.3 ± 2.9 |
13.5 ± 2.3 |
<0.05 |
RA vs HC: 0.0015 |
| CRP (mg/L), mean ± SEM |
12.2 ± 2.3 |
10.4 ± 2.1 |
5.7 ± 1.6 |
<0.0001 |
RA vs HC: 0.001
AS vs HC : < 0.0001 |
M: Male; F: Female; DAS28: Disease Activity Score 28 joints; HAQ: Health
Assessment Questionnaire; BASDAI: Bath Ankylosing Spondylitis Disease Activity
Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASDAS: Ankylosing
Spondylitis Disease Activity Score; MTX: Methotrexate; LFM: Leflunomide; SLZ:
Sulfasalazine; HCQ: Hydroxychloroquine; CTC: Corticosteroids; ESR: Erythrocyte
Sedimentation Rate; CRP: C-Reactive Protein
*Kruskal-Wallis test [level of significance was <0.05]
#post hoc Dunn test [level of significance was <0.016]
**Chi square test
***Mann-Whitney test). NA: not applicable |
